A new vaccine against COVID-19 is being carried out on the meta line, although Novavax has informed the youth that its product avoids hospitalizations and failures during the tests carried out in Great Britain and South Africa, including coronavirus mutations.
In a study carried out on 15,000 people in Great Britain, the Novavax inoculation showed a 90% efficiency in living, moderate and severe cases of COVID-19, the company informs. Of 106 confirmed deaths, 10 occurred in persons receiving the vaccine and 96 in participants to those who applied for a placebo.
Only five of the cases would be severe, all in the placebo group. Four of them were provoked by a more contagious variant that was discovered in Great Britain. Novavax determined that the vaccine had an 96% efficacy to combat inflammatory pathogens induced by the original virus, and 86% against the mutation.
In South Africa, one of the most preoccupying variants is rapidly expanding. Novavax studied 3,000 people in the country, some of the VIH paddles. The company signals that the vaccine will be effective at 55% against COVID-19 syndromes among volunteers who do not have VIH. As in Gran Bretaña, the only cases that are serious are between the participants who receive the placebo.
“The general panorama is that our vacancy works against the variants”, said Novavax’s CEO Stanley Erck.
Erck added that he would like to present his congratulations on the health measures of the United Kingdom in the principles of the second quarter in order to approve the extension of the vacancy. The company also pays the results of a study carried out between 30,000 people in the United States.
The recommendation: